[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07674680":3,"trial-entities:NCT07674680":95,"trial-summary:NCT07674680":99},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":6,"overall_status":7,"completion_date":8,"status_verified_date":9,"last_update_date":10,"start_date":11,"sponsor_name":12,"lead_sponsor_class":13,"has_dmc":14,"brief_summary":15,"detailed_description":16,"conditions":17,"keywords":21,"study_type":22,"primary_purpose":23,"phases":24,"enrollment_info":26,"interventions":29,"primary_outcomes":41,"secondary_outcomes":46,"sex":47,"minimum_age":48,"maximum_age":49,"healthy_volunteers":14,"eligibility_criteria":50,"std_ages":71,"locations":74,"central_contacts":90,"overall_officials":92,"references":93,"see_also_links":94},"NCT07674680","2135088","Beta3-adrenergic Receptors and Cardiovascular Function in Aging Women","NOT_YET_RECRUITING","2029-05","2026-06","2026-07-28","2026-07","University of Missouri-Columbia","OTHER",true,"To determine if vascular beta3 adrenergic receptors are present and functional in aging women and can be targeted to attenuate sympathetic vasoconstriction and enhance vascular function in aging women.",null,[18,19,20],"Women","Aging","Menopause",[],"INTERVENTIONAL","BASIC_SCIENCE",[25],"EARLY_PHASE1",{"count":27,"type":28},60,"ESTIMATED",[30,37],{"type":31,"name":32,"description":33,"armGroupLabels":34},"DRUG","Placebo","Participants will receive a placebo in pill form.",[35,36],"Cold pressor test","Flow Mediated Dilation",{"type":31,"name":38,"description":39,"armGroupLabels":40},"Gemtesa","Participants will receive oral gemtesa (75 mg).",[35,36],[42],{"measure":43,"description":44,"timeFrame":45},"Blood flow","Blood flow measured with Doppler ultrasound.","Change from baseline to minute 2.",[],"FEMALE","18 Years","70 Years",{"inclusion":51,"exclusion":56,"raw_text":70},[52,53,54,55],"Healthy women,","Assigned female at birth,","18-70 years of age,","Body mass index \\\u003C18 or ≥30 kg\u002Fm2,",[57,58,59,60,61,62,63,64,65,66,67,68,69],"Assigned male at birth,","Pregnancy,","Breastfeeding,","History of hormone replacement therapy, chemical menopause, or oophor-ectomy","Polycystic ovarian syndrome or Primary ovarian insufficiency,","Current smoking\u002FNicotine use,","Blood pressure ≥140\u002F90 mmHg,","Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy,","Nerve\u002Fneurologic disease,","Cardiovascular, hepatic, renal, respiratory disease,","Hypersensitivity to nitroglycerin,","Diabetes,","Communication barriers,","Inclusion Criteria:\n\n* Healthy women,\n* Assigned female at birth,\n* 18-70 years of age,\n* Body mass index \\\u003C18 or ≥30 kg\u002Fm2,\n\nExclusion Criteria:\n\n* Assigned male at birth,\n* Pregnancy,\n* Breastfeeding,\n* History of hormone replacement therapy, chemical menopause, or oophor-ectomy\n* Polycystic ovarian syndrome or Primary ovarian insufficiency,\n* Current smoking\u002FNicotine use,\n* Blood pressure ≥140\u002F90 mmHg,\n* Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy,\n* Nerve\u002Fneurologic disease,\n* Cardiovascular, hepatic, renal, respiratory disease,\n* Hypersensitivity to nitroglycerin,\n* Diabetes,\n* Communication barriers,",[72,73],"ADULT","OLDER_ADULT",[75],{"facility":76,"city":77,"state":78,"zip":79,"country":80,"contacts":81,"geoPoint":87},"University of Missouri","Columbia","Missouri","65211","United States",[82],{"name":83,"role":84,"phone":85,"email":86},"Jacqueline Limberg Associate Professor","CONTACT","1-573-882-2544","limberglab@missouri.edu",{"lat":88,"lon":89},38.95171,-92.33407,[91],{"name":83,"role":84,"phone":85,"email":86},[],[],[],{"nct_id":4,"conditions":96,"biomarkers":98},[19,97],"Menopause present",[],{"nct_id":4,"found":14,"summary":100,"prompt_version":109},{"design":101,"status":102,"heading":6,"summary":103,"follow_up":104,"word_count":105,"commitments":106,"compensation":107,"drugs_mentioned":108},"This is an interventional study, meaning participants will receive either Gemtesa or a placebo (an inactive pill). It plans to enroll 60 participants.","completed","This study is looking at how a medication called Gemtesa affects blood flow in aging women. Researchers want to see if Gemtesa, which targets certain receptors (beta3 adrenergic receptors) in the body, can improve blood vessel function. You might be able to join if you are a healthy woman between 18 and 70 years old, assigned female at birth, and meet specific body mass index (BMI) requirements. You cannot participate if you are pregnant, breastfeeding, or have a history of hormone replacement therapy, certain ovarian conditions, or currently smoke. The main goal is to measure changes in blood flow from the beginning of the study to two minutes after receiving the treatment. The study is currently unclear about its recruitment status and plans to enroll 60 participants.","Blood flow will be measured at two minutes after treatment to assess the primary outcome.",127,"Not specified in the trial record.","Not stated in the trial record.",[38],"v2"]